Drugs / CMV hyperimmune globulin
CMV hyperimmune globulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01376778 Comparator | Apr 2012 → Oct 2019 | cytomegalovirus infection | The George Washington University Biostatistics Center | Completed | No outcome recorded |
| Phase 4 | NCT01509404 Comparator | Nov 2011 → Dec 2014 | cytomegalovirus infection | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV hyperimmune globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01509404 ↗ |
| Modality | Protein / enzyme biologic | “immunoglobulin G (IgG) containing a standardized amount of antibody to CMV” NCT01376778 ↗ |
| Route | Intravenous | “is administered intravenously at a dose of 100 mg/kg body weight.” NCT01376778 ↗ |